Rates of CRS and ICANS
| Characteristics . | Patients (n = 12) . |
|---|---|
| CRS* | |
| Any CRS | 7/12 |
| Grade 1 | 7/12 |
| Grade 2 | — |
| Grade 3 | — |
| Grade 4 | — |
| Required tocilizumab | — |
| Median onset of CRS (day postinfusion) | 4 |
| Median duration of CRS (day postinfusion) | 2 |
| ICANS* | |
| Any ICANS | 6/12 |
| Grade 1 | 3/12 |
| Grade 2 | 2/12 |
| Grade 3 | 1/12 |
| Grade 4 | — |
| Required corticosteroids | |
| At time of infusion for disease control† | 4/12 |
| Additional provided for ICANS following infusion | 6/12 |
| Median onset (day postinfusion) | 5 |
| Median duration (day postinfusion) | 3 |
| Characteristics . | Patients (n = 12) . |
|---|---|
| CRS* | |
| Any CRS | 7/12 |
| Grade 1 | 7/12 |
| Grade 2 | — |
| Grade 3 | — |
| Grade 4 | — |
| Required tocilizumab | — |
| Median onset of CRS (day postinfusion) | 4 |
| Median duration of CRS (day postinfusion) | 2 |
| ICANS* | |
| Any ICANS | 6/12 |
| Grade 1 | 3/12 |
| Grade 2 | 2/12 |
| Grade 3 | 1/12 |
| Grade 4 | — |
| Required corticosteroids | |
| At time of infusion for disease control† | 4/12 |
| Additional provided for ICANS following infusion | 6/12 |
| Median onset (day postinfusion) | 5 |
| Median duration (day postinfusion) | 3 |